vs
莫德纳（MRNA）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是莫德纳的1.4倍（$1.4B vs $1.0B），莫德纳净利率更高（-19.7% vs -22.3%，领先2.6%），罗布乐思同比增速更快（43.2% vs -45.4%），罗布乐思自由现金流更多（$308.6M vs $-880.0M），过去两年罗布乐思的营收复合增速更高（32.9% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
MRNA vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.4倍
$1.0B
营收增速更快
RBLX
高出88.6%
-45.4%
净利率更高
MRNA
高出2.6%
-22.3%
自由现金流更多
RBLX
多$1.2B
$-880.0M
两年增速更快
RBLX
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.4B |
| 净利润 | $-200.0M | $-316.0M |
| 毛利率 | 79.6% | 77.7% |
| 营业利润率 | -25.6% | -25.3% |
| 净利率 | -19.7% | -22.3% |
| 营收同比 | -45.4% | 43.2% |
| 净利润同比 | -1638.5% | -43.9% |
| 每股收益（稀释后） | $-0.51 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNARBLX
| Q4 25 | — | $1.4B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $966.0M | $988.2M | ||
| Q3 24 | $1.9B | $919.0M | ||
| Q2 24 | — | $893.5M | ||
| Q1 24 | — | $801.3M |
净利润MRNARBLX
| Q4 25 | — | $-316.0M | ||
| Q3 25 | $-200.0M | $-255.6M | ||
| Q2 25 | — | $-278.4M | ||
| Q1 25 | — | $-215.1M | ||
| Q4 24 | $-1.1B | $-219.6M | ||
| Q3 24 | $13.0M | $-239.3M | ||
| Q2 24 | — | $-205.9M | ||
| Q1 24 | — | $-270.6M |
毛利率MRNARBLX
| Q4 25 | — | 77.7% | ||
| Q3 25 | 79.6% | 78.2% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | 23.5% | 77.9% | ||
| Q3 24 | 72.4% | 77.7% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 77.7% |
营业利润率MRNARBLX
| Q4 25 | — | -25.3% | ||
| Q3 25 | -25.6% | -21.8% | ||
| Q2 25 | — | -29.8% | ||
| Q1 25 | — | -24.6% | ||
| Q4 24 | -129.0% | -24.7% | ||
| Q3 24 | -3.8% | -30.4% | ||
| Q2 24 | — | -26.6% | ||
| Q1 24 | — | -37.7% |
净利率MRNARBLX
| Q4 25 | — | -22.3% | ||
| Q3 25 | -19.7% | -18.8% | ||
| Q2 25 | — | -25.8% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | -115.9% | -22.2% | ||
| Q3 24 | 0.7% | -26.0% | ||
| Q2 24 | — | -23.0% | ||
| Q1 24 | — | -33.8% |
每股收益（稀释后）MRNARBLX
| Q4 25 | — | $-0.44 | ||
| Q3 25 | $-0.51 | $-0.37 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | $-2.91 | $-0.32 | ||
| Q3 24 | $0.03 | $-0.37 | ||
| Q2 24 | — | $-0.32 | ||
| Q1 24 | — | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $9.3B | $394.5M |
| 总资产 | $12.1B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资MRNARBLX
| Q4 25 | — | $3.1B | ||
| Q3 25 | $1.1B | $2.9B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | $1.9B | $2.4B | ||
| Q3 24 | $1.6B | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.4B |
总债务MRNARBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MRNARBLX
| Q4 25 | — | $394.5M | ||
| Q3 25 | $9.3B | $407.6M | ||
| Q2 25 | — | $353.2M | ||
| Q1 25 | — | $310.7M | ||
| Q4 24 | $10.9B | $221.4M | ||
| Q3 24 | $11.9B | $189.9M | ||
| Q2 24 | — | $121.5M | ||
| Q1 24 | — | $71.6M |
总资产MRNARBLX
| Q4 25 | — | $9.6B | ||
| Q3 25 | $12.1B | $8.6B | ||
| Q2 25 | — | $7.8B | ||
| Q1 25 | — | $7.5B | ||
| Q4 24 | $14.1B | $7.2B | ||
| Q3 24 | $15.8B | $6.7B | ||
| Q2 24 | — | $6.5B | ||
| Q1 24 | — | $6.3B |
负债/权益比MRNARBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $308.6M |
| 自由现金流率自由现金流/营收 | -86.6% | 21.8% |
| 资本支出强度资本支出/营收 | 3.2% | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $1.4B |
8季度趋势，按日历期对齐
经营现金流MRNARBLX
| Q4 25 | — | $607.0M | ||
| Q3 25 | $-847.0M | $546.2M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $443.9M | ||
| Q4 24 | $825.0M | $184.5M | ||
| Q3 24 | $-1.6B | $247.4M | ||
| Q2 24 | — | $151.4M | ||
| Q1 24 | — | $238.9M |
自由现金流MRNARBLX
| Q4 25 | — | $308.6M | ||
| Q3 25 | $-880.0M | $443.6M | ||
| Q2 25 | — | $176.7M | ||
| Q1 25 | — | $426.5M | ||
| Q4 24 | $303.0M | $120.6M | ||
| Q3 24 | $-1.7B | $218.0M | ||
| Q2 24 | — | $111.7M | ||
| Q1 24 | — | $192.3M |
自由现金流率MRNARBLX
| Q4 25 | — | 21.8% | ||
| Q3 25 | -86.6% | 32.6% | ||
| Q2 25 | — | 16.3% | ||
| Q1 25 | — | 41.2% | ||
| Q4 24 | 31.4% | 12.2% | ||
| Q3 24 | -92.2% | 23.7% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 24.0% |
资本支出强度MRNARBLX
| Q4 25 | — | 21.1% | ||
| Q3 25 | 3.2% | 7.5% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | 54.0% | 6.5% | ||
| Q3 24 | 8.1% | 3.2% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 5.8% |
现金转化率MRNARBLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -120.46× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RBLX
暂无分部数据
